Moreover, we investigated the proteasomal inhibitor Bortezomib in combination with other classes of anti-cancer drugs in order to investigate the synergistic effects, based on previous publications, with Bortezomib on cancer cell killing, either alone or in a combination of microtubule-binding drug and CDK4/6 inhibitors [27,28]. This evidence concerns the gene CDK4 and cancer.